NASDAQ$ACRS
Aclaris Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Aclaris Therapeutics Inc reported Q2 2025 financial results with total revenue of $1.8 million and a net loss of $15.4 million.
The company recorded total revenue of $1.8 million for the three months ended June 30, 2025, driven by licensing and contract research activities. Operating expenses increased year-over-year, resulting in a net loss of $15.4 million or $0.13 per share. Cash and cash equivalents stood at $25.4 million with total assets of $189.1 million at quarter end.
- Total revenue declined to $1.8 million from $2.8 million in Q2 2024 due to lower licensing and contract research income.
- R&D expenses rose to $11.4 million, reflecting increased investment in bosakitug, ATI-2138 and ATI-052 programs.
- Net loss widened to $15.4 million compared to $11.0 million in the prior-year quarter.
- Cash position remained stable at $25.4 million with marketable securities providing additional liquidity of $155.5 million.
Headline financials
Revenue & EPS history
Aclaris Therapeutics · Revenue · Quarterly
$1.78M
Revenue by segment
Aclaris Therapeutics · $1.78M total across 2 segments · Q2 2025
- Licensing$1.34M—75.1%
- Contract research$442K—24.9%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.7%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+22.7%
Q4 2018
Best reaction
-15.3%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +1.7% | +1.9% | -8.8% | |
| Q4 2025 | -5.2% | -8.2% | +6.3% | |
| Q3 2025 | -4.7% | -9.7% | +23.7% | |
| Q1 2025 | -0.8% | -3.8% | +9.9% | |
| Q4 2024 | -7.1% | -8.1% | -24.3% | |
| Q3 2024 | +10.4% | +18.5% | +77.5% | |
| Q2 2024 | -4.1% | -6.6% | -4.1% | |
| Q1 2024 | -6.9% | -10.7% | -21.4% | |
| Q4 2023 | -1.7% | +2.5% | +2.5% | |
| Q3 2023 | +0.9% | -11.5% | -81.0% | |
| Q2 2023 | -12.1% | -16.5% | -23.4% | |
| Q1 2023 | -7.8% | -12.1% | +4.5% | |
| Q4 2022 | -4.9% | -1.8% | -36.9% | |
| Q3 2022 | +4.3% | +9.3% | -0.2% | |
| Q2 2022 | +18.1% | +26.8% | +20.6% | |
| Q1 2022 | -8.9% | -4.5% | +35.3% | |
| Q4 2021 | +14.3% | +11.3% | +33.5% | |
| Q3 2021 | -12.4% | -11.0% | -31.4% | |
| Q2 2021 | +4.1% | +1.4% | +21.2% | |
| Q1 2021 | -2.2% | -8.6% | -8.8% | |
| Q4 2020 | +7.8% | +12.5% | +11.4% | |
| Q3 2020 | +7.0% | +7.5% | +0.8% | |
| Q2 2020 | +11.3% | +12.8% | +9.7% | |
| Q1 2020 | +12.7% | +10.3% | +13.5% | |
| Q4 2019 | -14.0% | -20.3% | -18.2% | |
| Q3 2019 | +20.4% | +11.7% | +2.5% | |
| Q2 2019 | -11.8% | -18.8% | -1.0% | |
| Q1 2019 | -11.2% | -14.7% | -29.0% | |
| Q4 2018 | +22.7% | +8.7% | -7.8% | |
| Q3 2018 | -1.8% | -13.2% | -29.8% | |
| Q2 2018 | -4.6% | -3.9% | -11.9% | |
| Q1 2018 | -0.5% | +4.2% | +1.4% | |
| Q4 2017 | -6.7% | -12.5% | -18.4% | |
| Q3 2017 | -5.7% | -3.2% | -7.9% | |
| Q2 2017 | -0.1% | -7.1% | +1.4% | |
| Q1 2017 | +6.3% | +5.8% | +0.6% | |
| Q4 2016 | -4.9% | -5.2% | +5.8% | |
| Q3 2016 | -1.0% | -2.7% | +39.7% | |
| Q2 2016 | +3.1% | +7.0% | +15.0% | |
| Q1 2016 | -15.3% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro